Overview

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas

Status:
Not yet recruiting

Trial end date:
2027-08-30

Target enrollment:

Participant gender:

Summary

Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant astrocytomas.

Phase:

Phase 1

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab